SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize targeted heat therapy to treat cancer, today announced that Dr. James G. Carlisle and his pioneering work with BSD's MicroThermX® Microwave Ablation System (MicroThermX®) were profiled in a recent issue of Utah Business. (Cutler, S, Lewis, DI, Francom, “Healthcare Heroes the Quiet Champions of Healing and Hope.”) The annual publication by Utah Business is devoted to health care workers who exemplify a devotion to bringing health and hope to patients. The authors discussed the innovative technology incorporated into the MicroThermX® and explained that, "This innovation surrounds a tumor with small antennas and heats it with microwaves until the tumor cells are destroyed." The authors explained that Dr. Carlisle was the first MicroThermX® specialist in Utah and is one of Utah's leading providers of groundbreaking treatments that improve care and make recovery easier for cancer patients. The authors noted that Dr. Carlisle uses the MicroThermX® as a method to improve patient outcome and reduce the negative impact of the treatment. The article is available at: http://dev.utahbusiness.com/articles/view/healthcare_heroes_1.
About the MicroThermX® Microwave Ablation System
The MicroThermX® is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX® introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX® System.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.